theory clinical_3_4
imports Main

begin

typedecl entity
typedecl event

consts
  LossOfBRCA2 :: "entity ⇒ bool"
  ChromosomeBreakage :: "entity ⇒ bool"
  Cause :: "event ⇒ bool"
  Agent :: "event ⇒ entity ⇒ bool"
  Patient :: "event ⇒ entity ⇒ bool"
  InhibitionOfPARP :: "entity ⇒ bool"
  CollapsedReplicationForks :: "entity ⇒ bool"
  DoubleStrandBreaks :: "entity ⇒ bool"
  Result :: "event ⇒ bool"
  PARPInhibitors :: "entity ⇒ bool"
  CancerDevelopment :: "entity ⇒ bool"
  GenomicInstability :: "entity ⇒ bool"
  Drive :: "event ⇒ bool"
  Via :: "event ⇒ entity ⇒ bool"
  TrappingOfPARP1 :: "entity ⇒ bool"
  NonHomologousEndJoining :: "entity ⇒ bool"
  Toxicity :: "entity ⇒ bool"
  Increase :: "event ⇒ bool"
  SingleStrandBreakRepair :: "entity ⇒ bool"
  ReplicationAssociatedDoubleStrandBreaks :: "entity ⇒ bool"
  Prevent :: "event ⇒ bool"
  Lead :: "event ⇒ bool"
  HomologousRecombinationRepair :: "entity ⇒ bool"
  Rely :: "event ⇒ bool"
  On :: "event ⇒ entity ⇒ bool"
  Repair :: "event ⇒ bool"
  PreventionOfSingleStrandBreakRepair :: "entity ⇒ bool"
  Through :: "event ⇒ entity ⇒ bool"

(* Explanation 1: Loss of BRCA2 causes chromosome breakage. *)
axiomatization where
  explanation_1: "∃x y e. LossOfBRCA2 x ∧ ChromosomeBreakage y ∧ Cause e ∧ Agent e x ∧ Patient e y"

(* Explanation 2: Inhibition of PARP results in collapsed replication forks and double strand breaks, and PARP inhibitors directly cause these double strand breaks. *)
axiomatization where
  explanation_2: "∃x y z e1 e2. InhibitionOfPARP x ∧ CollapsedReplicationForks y ∧ DoubleStrandBreaks z ∧ Result e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Patient e1 z ∧ PARPInhibitors x ∧ Cause e2 ∧ Agent e2 x ∧ Patient e2 z"

(* Explanation 3: Loss of BRCA2 drives cancer development via genomic instability. *)
axiomatization where
  explanation_3: "∃x y z e. LossOfBRCA2 x ∧ CancerDevelopment y ∧ GenomicInstability z ∧ Drive e ∧ Agent e x ∧ Patient e y ∧ Via e z"

(* Explanation 4: Trapping of PARP1 at sites of double strand breaks increases non-homologous end joining and increases toxicity. *)
axiomatization where
  explanation_4: "∃x y z e1 e2. TrappingOfPARP1 x ∧ DoubleStrandBreaks y ∧ NonHomologousEndJoining z ∧ Toxicity z ∧ Increase e1 ∧ Agent e1 x ∧ Patient e1 z ∧ Increase e2 ∧ Agent e2 x ∧ Patient e2 z"

(* Explanation 5: PARP inhibitors prevent single strand break repair, which leads to replication-associated double strand breaks. *)
axiomatization where
  explanation_5: "∃x y z e1 e2. PARPInhibitors x ∧ SingleStrandBreakRepair y ∧ ReplicationAssociatedDoubleStrandBreaks z ∧ Prevent e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Lead e2 ∧ Agent e2 y ∧ Patient e2 z"

(* Explanation 6: PARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)
axiomatization where
  explanation_6: "∃x y z e1 e2. PARPInhibitors x ∧ HomologousRecombinationRepair y ∧ NonHomologousEndJoining z ∧ Rely e1 ∧ Agent e1 x ∧ On e1 y ∧ On e1 z ∧ Repair e2 ∧ Agent e2 x"

(* Explanation 7: The prevention of single strand break repair by PARP inhibitors results in replication-associated double strand breaks, which are then repaired through defective homologous recombination repair and error-prone non-homologous end joining. *)
axiomatization where
  explanation_7: "∃x y z e1 e2. PreventionOfSingleStrandBreakRepair x ∧ PARPInhibitors y ∧ ReplicationAssociatedDoubleStrandBreaks z ∧ Result e1 ∧ Agent e1 x ∧ Patient e1 z ∧ Repair e2 ∧ Agent e2 z ∧ Through e2 y"

(* Explanation 8: PARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks. *)
axiomatization where
  explanation_8: "∃x y z e1 e2 e3. PARPInhibitors x ∧ DoubleStrandBreaks y ∧ SingleStrandBreakRepair z ∧ ReplicationAssociatedDoubleStrandBreaks z ∧ Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Prevent e2 ∧ Agent e2 x ∧ Patient e2 z ∧ Lead e3 ∧ Agent e3 y ∧ Patient e3 z"

theorem hypothesis:
  assumes asm: "PARPInhibitors x ∧ DoubleStrandBreaks y ∧ SingleStrandBreakRepair z"
  (* Hypothesis: PARP inhibitors cause replication‐associated double strand breaks by preventing single strand break repair, relying on defective homologous recombination repair and error prone non-homologous end joining to repair DNA. *)
  shows "∃x y z e1 e2 e3 e4. PARPInhibitors x ∧ DoubleStrandBreaks y ∧ SingleStrandBreakRepair z ∧ Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Prevent e2 ∧ Agent e2 x ∧ Patient e2 z ∧ Rely e3 ∧ Agent e3 x ∧ On e3 z ∧ Repair e4 ∧ Agent e4 x ∧ Patient e4 y"
proof -
  (* From the premise, we have known information about PARP inhibitors, double strand breaks, and single strand break repair. *)
  from asm have "PARPInhibitors x ∧ DoubleStrandBreaks y ∧ SingleStrandBreakRepair z" by simp
  (* Explanation 8 states that PARP inhibitors cause double strand breaks by preventing single strand break repair, which leads to replication-associated double strand breaks. *)
  (* We can use this to infer the cause and prevention relations. *)
  then obtain e1 e2 e3 where "Cause e1 ∧ Agent e1 x ∧ Patient e1 y ∧ Prevent e2 ∧ Agent e2 x ∧ Patient e2 z ∧ Lead e3 ∧ Agent e3 y ∧ Patient e3 z" sledgehammer
  (* Explanation 6 states that PARP inhibitors rely on defective homologous recombination repair and error-prone non-homologous end joining to repair DNA. *)
  (* We can use this to infer the rely and repair relations. *)
  then obtain e3 e4 where "Rely e3 ∧ Agent e3 x ∧ On e3 z ∧ Repair e4 ∧ Agent e4 x ∧ Patient e4 y" <ATP>
  (* Combining these, we can construct the hypothesis. *)
  then show ?thesis <ATP>
qed

end
